Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

Huge crowds have come out to Chinatown for Lunar New Year as new political faces take office. She made the look her own with ...

Eli Lilly started 2024 on a strong note but struggled during the second half of the year. The drugmaker dealt with several ...

President Donald Trump signed an executive order pulling the U.S. out of the W.H.O. Winter health woes from the dangerous ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

Headlines,Eli Lilly Shares Experience a Decline,Key Analyst Activity and Ratings for LLY,What's Next for Eli Lilly's ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Eli Lilly & Co. (LLY) is rebounding from Friday's sales disappointment, finding support at $722 and set for another uptrend.